Shuttle Pharmaceuticals (NASDAQ:SHPH) Trading Up 16.8% – Still a Buy?

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH)’s stock price was up 16.8% on Monday . The stock traded as high as $1.77 and last traded at $1.67. Approximately 263,739 shares were traded during trading, a decline of 50% from the average daily volume of 530,633 shares. The stock had previously closed at $1.43.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (e)” rating on shares of Shuttle Pharmaceuticals in a research report on Tuesday, November 18th. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Shuttle Pharmaceuticals Trading Up 16.8%

The firm has a market cap of $2.67 million, a P/E ratio of -0.14 and a beta of -0.87. The firm’s 50 day moving average is $3.06 and its two-hundred day moving average is $3.60.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its earnings results on Thursday, November 13th. The company reported ($1.05) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Shuttle Pharmaceuticals stock. Connective Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned 9.40% of Shuttle Pharmaceuticals as of its most recent SEC filing. 4.58% of the stock is owned by institutional investors.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .